mortality following HK was 26%, versus 6% in matched non-HK patients. Compared with non-HK patients, 6-month hazard ratios for any acute hospitalization in HK patients were 2.11-fold higher, including hazard ratios of 2.07 for cardiac diagnoses, 2.29 for ventricular arrhythmias, 3.26 for cardiac arrest, 4.77 for intensive care and 4.85 for death. Conclusions. More than one in four CKD patients develops HK. Patients with severe CKD, diabetes, heart failure or use of spironolactone are at high risk. HK is associated with severe clinical outcomes.
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I N T R O D U C T I O N
Hyperkalemia (HK) is common in patients with chronic kidney disease (CKD), but population-based data on its incidence, risk factors and prognosis are scarce [1] [2] [3] . HK (usually defined as a blood potassium level >5.0 mmol/L [4, 5] ) occurs in 1-10% of all hospitalized patients [6, 7] . Risk factors for HK, in addition to kidney disease, include old age, cancer, volume depletion, metabolic acidosis and acute cell-tissue breakdown [2, 4, 8] . Commonly used drugs also may lead to HK by interfering with renal potassium excretion, including angiotensin-converting enzyme inhibitors (ACEis), angiotensin receptor II blockers (ARBs) and potassium-sparing diuretics such as spironolactone and eplerenone [4, 9] . Potassium levels > 6.0 mmol/L may lead to cardiac arrhythmias and death [3, 9] , as evidenced in clinical case series [10, 11] . However, in single clinic or health insurance-based studies, even potassium levels > 5.0 or 5.5 mmol/L have been predictive of short-term mortality and cardiovascular events among patients with an acute hospitalization [7] or CKD [12] [13] [14] .
To better understand the true burden of HK and the potential role of new drug therapies for HK [3, 15] , it is important to examine the incidence, risk factors and clinical outcomes of HK in patients with CKD in real-world settings. We therefore conducted a large population-based cohort study in Denmark to assess the burden of HK in patients with incident CKD.
M A T E R I A L S A N D M E T H O D S

Setting
This cohort study was conducted in northern Denmark using routine laboratory test results from both primary and hospital care for the entire region's population of 1.8 million residents (30% of Denmark's population) since 2000 [16] . The laboratory data were linked with hospital diagnoses and procedure data from the Danish National Patient Registry (DNPR), which contains dates of hospital admission and discharge, emergency room and outpatient clinic visit dates, procedures and primary and secondary diagnoses codes from all Danish hospitals [17] . Furthermore, data on prescribed drugs were retrieved from prescription databases, which contains records of the type of drug, date of dispensing and quantity of all prescribed drugs dispensed from Danish pharmacies in northern Denmark [18, 19] .
Patients with CKD
From the source population of all individuals living in northern Denmark between 2000 and 2012 [20] , we identified a cohort of patients with an incident CKD diagnosis, defined as the first occurrence of one of the following: (i) a second creatinine measurement, > 90 days following a prior measurement, corresponding to a second estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m 2 [21] ; (ii) an incident hospitalization with a diagnosis of CKD or (iii) hospital-based codes for renal dialysis (see Supplementary data, Appendix for codes used). 
Baseline data and follow-up
Baseline characteristics on the index date of the incident CKD diagnosis were based on dispensed drugs from pharmacies within the last 12 months and on diagnoses and procedures in the DNPR up to and including the CKD index date (see Supplementary data, Appendix for codes). Patients were followed for HK starting from the CKD index date until migration, death or end of follow-up.
For the analyses of clinical outcomes associated with HK, we ascertained complete data on all drug prescriptions and outpatient and inpatient hospital contacts occurring 6 months before the HK event date and again 6 months including and after the HK event date. These data were ascertained for CKD patients who developed HK and for HK index date-matched CKD controls (see 'Statistical analysis' section). Inpatient hospitalizations were further divided into non-acute and acute hospitalizations, and the latter events were categorized by associated cardiac diagnoses, dialysis and ventilator treatment and intensive care unit (ICU) therapy (see Supplementary data, Appendix for codes used).
Statistical analysis
Incidence of HK. We examined the incidence of a first HK event [elevated blood potassium level (K þ ) >5.0 mmol/L not preceded by a prior episode of elevated K þ within the previous month] per 1000 years at risk, overall and by subgroups. The incidence of HK events with K þ >5.5 mmol/L and events with K þ >6.0 mmol/L was separately analysed. Cumulative incidence function curves were constructed and risks (cumulative incidence proportions) of developing a first HK event within 1 and 3 years were estimated. The risks of developing a second, third and fourth HK event were also described.
Risk factors for HK. To examine risk factors prior to the HK event, one CKD comparison patient without HK was matched to each CKD patients with HK on the date of HK diagnosis (defined as the index date) according to age, gender, year, and time since CKD diagnosis. Prevalence ratios (PRs) with 95% confidence intervals (CIs) were calculated for the association of specified risk factors with HK.
Outcomes associated with HK. Two methods were used to examine clinical outcomes.
In a before-after analysis among CKD patients who had all experienced HK, the cumulative incidence proportion ratios [risk ratios (RRs)] of experiencing each individual clinical outcome during the 6 months after versus 6 months before the HK event date were calculated, accounting for competing risk of death within 6 months after the HK date.
In a matched cohort design, Cox regression was used to estimate the hazard ratio (HR) of clinical outcomes 6 months after the HK/index date in CKD-HK patients versus a cohort of fully matched non-HK comparison patients. In contrast to the risk factor analysis, these comparisons were not only matched on gender, age and time since CKD, but additionally matched on CKD stage (eGFR category), Charlson Comorbidity Index (CCI) score category, presence of selected HK-associated conditions (diabetes, congestive heart failure or hypertension), and use of HK-associated drugs [ACEis, ARBs, potassium-sparing diuretics (spironolactone or eplerenone) or potassium supplements]. To account for remaining unmeasured confounding, the ratio of the two matched HRs observed after versus before the HK/index date, that is, the prior event rate ratio-adjusted rate ratio was estimated [23] .
All outcome analyses were repeated for events with K þ >5.5 mmol/L and >6.0 mmol/L, respectively. Sensitivity analyses. To better assess whether HK predicted hospitalization outcomes, such as ICU admission, rather than being a possible consequence of these events during the admission course, outcomes were also examined separately for HK detected on the first admission date of any hospitalization.
All analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC, USA).
R E S U L T S
Baseline characteristics
In total, 157 766 persons with a first-incident diagnosis of CKD in northern Denmark during 2000-2012 were identified. The median age was 73 [interquartile range (IQR) 63-81)] years and 59% were women. Half of the patients (53%) had a CCI score !1 (excluding kidney disease); 15% had concomitant diabetes, 9% had heart failure and 55% had hypertension. At baseline, 23% were treated with ACEis, 14% with ARBs, 8% with potassium-sparing diuretics (99% spironolactone) and 17% with potassium supplements (Table 1) .
Incidence of HK
During 615 890 patient-years of follow-up [median followup 2.9 years, median number of (K þ ) tests 13], 28% (n ¼ 43 397) of CKD patients experienced a first HK event (elevated K þ >5.0 mmol/L), corresponding to an overall incidence rate of 70 per 1000 person-years (Table 1) . HK incidence increased with CKD severity, and the highest rates were observed in patients with CKD Stages 3B, 4 or 5, at 119, 239 and 333 events per 1000 person-years, respectively (Table 1) . Incidence rates also increased with age, comorbidity burden and other factors, as shown in Supplementary data, Table S1 . Within the first year following CKD diagnosis, 128 of 1000 patients overall developed HK. Among patients with CKD Stages 3A, 3B, 4 or 5, respectively, 9, 18, 31 and 42% experienced HK within the first year following CKD diagnosis. The median time to the first HK event was 1.2 years in patients experiencing an event, among whom 20 138 (47%) had a hospital-based diagnosis. Figure 1 shows the cumulative incidence curves of the first HK events. The cumulative risk of HK in the entire CKD population was 12.8% during the first year and 19.4% 3 years after CKD diagnosis. The incidence curves were steepest in the first months after CKD diagnosis, particularly for patients with Stage 4 or 5 CKD or dialysis. However, the proportion of patients experiencing HK continued to increase over time ( Figure 1 ). The incidence of HK clearly increased with declining renal function, although dialysis patients had lower HK rates than Stage 5 patients without dialysis.
Almost half (43%) of all patients with a first HK event had a second event ( Figure 2 ). Patient proportions who experienced a third (57%) or fourth (64%) HK event after previous events were even greater, with successively shorter follow-up times.
Supplementary data, Figure S1 shows the risks of repeated events for patients with a first event with potassium levels >5.5 or >6.0 mmol/L.
Risk factors for HK
Patients who developed HK had more severe CKD than age-, gender, year-and duration-matched CKD comparison patients without HK (e.g. Stages 4 and 5 CKD observed in 21% and 6% of patients with HK versus 7% and 2% of patients without HK) ( Table 2) . ACEis, ARBs, potassium-sparing diuretics (spironolactone) and potassium supplements were used by 36, 18, 19 and 31% of patients, respectively, at the time of HK diagnosis, more than was used by non-HK patients. In particular, patients with HK were more likely to have heart failure [PR 2.3 (95% CI 2.2-2. Table S2 . The relative importance of most risk factors increased with higher levels of K þ .
Clinical outcomes associated with HK
In CKD patients with HK, the risk of having at least one acute hospitalization event was 34% within 6 months before the HK event, increasing to 57% 6 months after the HK event, corresponding to an after versus before relative risk (RR) of 1.72 (95% CI 1.69-1.74) ( Supplementary data, Table S3 shows clinical outcomes separately for endpoints of K þ >5.5 mmol/L and >6.0 mmol/L. The RRs generally increased with more pronounced K þ elevations. For example, the after versus before RR for any acute hospitalization was 1.7-fold greater for K þ >5.0, while it was 1.8-fold and 1.9-fold greater for K þ levels of >5.5 and >6.0 mmol/ L, respectively. Corresponding after versus before RRs for ventricular arrhythmias and cardiac arrest were 2.1 and 10.7 for K þ >5.0, 2.2 and 16.3 for K þ >5.5 and 2.6 and 27.2 for K þ >6.0 mmol/L. Sensitivity analyses restricted to patients who survived at least 6 months after the HK/index date yielded outcomes very similar to those from competing risk of death analyses (data not shown). For patients whose HK was already confirmed on the admission date of any hospitalization, RRs of clinical outcomes were higher than for the overall HK cohort; for example, the after versus before RR for any acute hospitalization was 2.2 versus 1.7 in the overall cohort and the HR compared with matched patients was 5.3 versus 2.1. Burden of hyperkalemia in kidney disease 
D I S C U S S I O N
This population-based cohort study provides a detailed overview of HK incidence, risk factors and prognosis in patients with incident CKD in a Northern European region over 13 years. Among CKD patients with incident Stage 4 disease, 3 of 10 experienced HK within a year. Among patients with Stage 5 disease, four out of ten experienced HK within a year. Recurrent HK episodes were common. Individuals who also had chronic heart failure and/or were treated with ACEis or spironolactone were at particularly increased risk of HK. HK was associated with severe clinical outcomes in CKD patients, including a 1.7-to 2-fold increased risk of ventricular arrhythmias, other cardiac diagnoses and acute hospitalizations compared with the 6-month period before HK in the same patients. Rates of these outcomes were 2.1-to 2.3-fold higher compared with matched CKD patients without HK, while the 6-month risk of death was almost 5-fold higher. Previous population-based data on HK in patients with CKD are scarce. Studies of patients with CKD have described frequencies of HK ranging widely, from 8% to 73%, depending on the population studied, follow-up period and definition of HK (typically defined as >5.0 or >5.5 mmol/L) [2] . Hayes et al. [24] found that among 1227 males with CKD followed for a median of 20 assessments at one medical center in the USA, 42% experienced at least one event of K þ >5.3 mmol/L. In our study, 28% of patients overall experienced K þ >5.0 mmol/L over a median of 2.9 years. Among the CKD patients in the Hayes et al. [24] study, many more had Stage 4 and 5 disease (31% and 5%, respectively) than patients in our study (6% and 3%, respectively). Consistent with the findings of Hayes et al., 48% and 59% of CKD patients in our study with Stage 4 and 5 disease experienced K þ >5.0 mmol/L. A registry-based national cohort study of patients cared for over a single year in the US Veterans Health Administration reported a rate of K þ >5.5 mmol/L of $8 per 100 patientmonths among CKD patients, considerably higher than the incidence of 70 per 1000 person-years found in our study, but apparently also counting multiple HK events [12] . Corroborating our results, the risk of HK increased with CKD stage and with the use of renin-angiotensin-aldosterone system (RAAS) inhibitors, diabetes and level of comorbidity [12] . Also consistent with our findings, three previous cohort studies found that potassium levels >5.0 or >5.5 mmol/L predicted short-term mortality and cardiovascular events among CKD patients [12] [13] [14] . Our observational study of the burden of HK in patients with CKD has both strengths and weaknesses. The Danish public tax-financed health care system permitted inclusion of all individuals with incident CKD and subsequent HK in a welldefined geographical region. This largely eliminated some of the selection problems encountered in clinic-based or health insurance-based observational studies.
The validity of our findings depends on the quality and completeness of registry data. Limitations include our reliance on potassium and other tests ordered in everyday clinical practice, for example, by medical indication for measurement. The positive predictive value in the DNPR of variables included in the CCI [17, 25] , cardiovascular diseases [26] , ICU admission and dialysis [27] is moderate to high. As we lacked diagnosis data from general practitioner (GP) practices, we had to rely on GPprescribed drugs. Our data thus may have been incomplete for less severe, lifestyle-treated conditions followed in primary care. Obtaining drugs from sources other than community pharmacies is unlikely because all reimbursed prescriptions have to be redeemed at such pharmacies in Denmark. Nonetheless, prescription redemption is just a marker of consumption of any drug and noncompliance is possible.
In the present study, a higher risk of HK was observed in CKD patients with a more severe CKD stage, corresponding to declining GFR, higher age and more comorbidities, especially CHF and diabetes. The risk of HK was greater in patients receiving RAAS inhibitor therapy or potassium supplements. These findings agree with the established important role of the renal distal tubular function in preserving normal potassium homeostasis. Regulation of renal potassium excretion in the distal convoluted tubuli and collecting ducts is dependent upon preserved diuresis and distal tubular flow, the RAAS and dietary adaptation in renal tubular expression of potassium channels. Thus our study findings in a large population reflect the pathophysiology of renal disease and well-known high prevalence of comorbidities in patients with CKD.
Any conclusions concerning causal mechanisms underlying HK outcomes should be made with caution. Rather than causing hospitalization, HK values obtained during an acute hospitalization may stem from the condition leading to hospitalization (e.g. infection, dehydration, deteriorating kidney function). The exact order of events in the pathophysiological pathway leading to an acute hospitalization is difficult to disentangle, particularly for elderly patients. In addition to arrhythmias and related cardiac dysfunction, HK may cause fatigue, weakness and nausea, leading to immobilization, falls and related events. It may thus be impossible to determine this pathway in a registry-based study, i.e. to determine in which cases HK did not have any bearing on the acute hospitalization and its course. Taken together, however, our findings suggest a possible causal association: outcome RRs increased successively for more severe versus mild potassium elevation, and specific diagnoses such as ventricular arrhythmias and cardiac arrest were closely associated with HK.
In conclusion, in this population-based study, a substantial proportion of CKD patients developed HK; patients with severe CKD, heart failure and those treated with spironolactone were at particularly increased risk. HK was associated with an increased risk of hospitalization, severe clinical outcomes and death in CKD patients.
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